These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 26297071)

  • 21. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.
    Messias K; Barroso RM; Jorge R; Messias A
    Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
    Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained and expedited resolution of diabetic papillopathy with combined PRP and bevacizumab.
    Chin EK; Almeida DR; Sohn EH
    Can J Ophthalmol; 2015 Oct; 50(5):e88-91. PubMed ID: 26455990
    [No Abstract]   [Full Text] [Related]  

  • 26. Determinants in Initial Treatment Choice for Diabetic Macular Edema.
    VanderBeek BL; Scavelli K; Yu Y
    Ophthalmol Retina; 2020 Jan; 4(1):41-48. PubMed ID: 31345726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor and diabetic macular edema.
    Lally DR; Shah CP; Heier JS
    Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The area of fixation covaries with short-term changes in visual acuity after anti-vascular endothelial growth factor treatment in patients with diabetic macular oedema.
    Jakobsen NS; Larsen DA; Bek T
    Acta Ophthalmol; 2018 Nov; 96(7):744-748. PubMed ID: 29687595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of therapies for diabetic macular oedema and rationale for combination therapy.
    Amoaku WM; Saker S; Stewart EA
    Eye (Lond); 2015 Sep; 29(9):1115-30. PubMed ID: 26113500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS.
    Ciulla TA; Hussain RM; Ciulla LM; Sink B; Harris A
    Retina; 2016 Jul; 36(7):1292-7. PubMed ID: 26583309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial.
    Figueira J; Silva R; Henriques J; Caldeira Rosa P; Laíns I; Melo P; Gonçalves Nunes S; Cunha-Vaz J
    Ophthalmologica; 2016; 235(1):34-41. PubMed ID: 26630400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema.
    Mohamed QA; Fletcher EC; Buckle M
    BMJ Clin Evid; 2016 Mar; 2016():. PubMed ID: 27031563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.
    Sorour OA; Sabrosa AS; Yasin Alibhai A; Arya M; Ishibazawa A; Witkin AJ; Baumal CR; Duker JS; Waheed NK
    Int Ophthalmol; 2019 Oct; 39(10):2361-2371. PubMed ID: 31119505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.